Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

  • Technology appraisal guidance
  • TA258
  • Published: 
Download guidance (PDF)

1 Guidance

1.1 Erlotinib is recommended as an option for the first-line treatment of people with locally advanced or metastatic non-small-cell lung cancer (NSCLC) if:

  • they test positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and

  • the manufacturer provides erlotinib at the discounted price agreed under the patient access scheme (as revised in 2012).